Innovent Biologics Reports 36.2% Revenue Growth in 2023, Highlights Robust Product Sales
Innovent Biologics Inc. (HKG: 1801), a China-based biotechnology firm, has released its 2023 financial report,...
Jiangsu Hengrui Receives NMPA Approval for Phase Ib/II Study of HRS2398 in Advanced Solid Tumors
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...
Zuellig Pharma Expands Commercialization Deal for Karo Healthcare’s Lamisil in Asian Markets
Zuellig Pharma, a Singapore-based healthcare solutions provider, has announced the expansion of its commercialization agreement...
CSPC Pharmaceutical Gets NMPA Greenlight for SYH2039 Clinical Study in Advanced Malignant Tumors
CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has received...
Novo Nordisk Invests RMB 4 Billion to Expand Sterile Manufacturing in Tianjin
Novo Nordisk (NYSE: NVO), a Denmark-based leader in diabetes care, has announced a substantial investment...
Suzhou Porton Biologics Partners with Kunshi Biotech to Advance Third-Generation CAR-M Therapy
Suzhou Porton Biologics Ltd, a China-based Contract Development and Manufacturing Organization (CDMO), has entered into...
China Expands Medical Service Pricing Reform with Three Additional Pilot Provinces
The National Healthcare Security Administration (NHSA) has announced an expansion of its medical services pricing...
Swiss Pharma Firm Carbogen Amcis Receives Brazil’s ANVISA GMP Certification for Shanghai Site
Carbogen Amcis, a Swiss firm specializing in active pharmaceutical ingredients (APIs) and pharmaceutical process development,...
Everest Medicines Strengthens Leadership with Appointments of Sandra Zeng and Rico Liang
Everest Medicines (HKG: 1952), a leading China-based biotechnology company, has announced two significant appointments to...
WuXi XDC Breaks Ground on State-of-the-Art Manufacturing Base in Singapore to Boost ADC Production
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...
Shanghai Winpu Technology and Silver Mars Merge Under YinKe Holding to Accelerate Healthcare Innovation
Shanghai Winpu Technology Co., Ltd., a specialist in medical-grade polymer materials based in China, has...
Everest Medicines’ Nefegan Approved by Singapore HSA for Primary IgAN Treatment
Everest Medicines (HKG: 1952), a China-based biotechnology company, has received marketing approval from the Singapore...
Shanghai Pharmaceuticals Appoints New Chairman Amid Leadership Shake-up
Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607), one of the leading pharmaceutical giants in China,...
AstraZeneca to Acquire Fusion Pharmaceuticals in a Deal Valued at USD 2.4 Billion
AstraZeneca (AZ; NASDAQ: AZN), the UK-based pharmaceutical giant, has announced its intention to acquire Fusion...
China Grand Pharmaceutical Reports Robust 2023 Revenues and Pipeline Advancements
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has reported its financial results...
Dr. Reddy’s Launches Biosimilar Versavo in UK to Challenge Roche’s Cancer Therapy Avastin
Dr. Reddy’s Laboratories (NYSE: RDY), a prominent Indian pharmaceutical company, has launched its biosimilar Versavo...
Bayer’s Elinzanetant Achieves Primary Endpoint in Late-Stage Menopause Symptom Trial
Bayer (ETR: BAYN), a leading German pharmaceutical company, has announced positive results from a placebo-controlled...
China Medical System Gets Green Light for Phase III Clinical Trial of Opzelura in Atopic Dermatitis
China Medical System Holdings (CMS; HKG: 0867) has received approval from the National Medical Products...
AstraZeneca’s Lynparza-Imfinzi Combo Shows Promising Results in Endometrial Cancer Study
AstraZeneca (AZ; NASDAQ: AZN), a UK-based pharmaceutical giant, has presented interim results from a late-stage...
China’s National Joint Procurement Office Sets March 2024 for Insulin Contracts Renewal
The National Joint Procurement Office in China has released a notification outlining the information and...